Ribavirin News and Research

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A

19. November 2009 09:35

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic. [More]

a89d6962-bca8-4ab0-a2e0-2b4ec61b3c24|0|.0

Posted in: Drug Trial News | Disease/Infection News

Tags: Antiviral Drug, Chemotherapy, H1N1, Influenza, Pandemic, Ribavirin, Virus

On-going Phase 2b study conducted by Roche of ITMN-191 modified

18. November 2009 03:55

InterMune, Inc. today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin) in HCV treatment-naive patients has been modified. [More]

4a9e6d1b-50ba-4abd-9d87-de4746276193|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Allopurinol, Biotechnology, Fibrosis, Hepatitis C, Hepatology, Idiopathic Pulmonary Fibrosis, New Drug Application, Peginterferon alfa, Pirfenidone, Ribavirin, Ritonavir, Toxicology, Virus

Idera Pharmaceuticals announces financial results for the third quarter of 2009

5. November 2009 07:54

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. [More]

8ff77ca2-571a-46e3-884c-ad4815778782|0|.0

Posted in: Business / Finance

Tags: Allergy, Antisense, Arthritis, Asthma, Avastin, Bevacizumab, Bone, Cancer, Cell, Collagen, Colorectal Cancer, Cytokines, Diarrhea, DNA, Erlotinib, Etanercept, Gene Expression, Headache, Hepatitis C, Kidney Cancer, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Oligonucleotides, Oncology, Pathology, Pfizer, Potassium, Renal Cell Carcinoma, Respiratory Disease, Rheumatology, Ribavirin, Small Cell Lung Cancer, Tarceva, Vaccine, Virus

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

4. November 2009 08:15

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. [More]

b81f12ab-a94e-45b4-a0c8-67be41264a74|0|.0

Posted in: Drug Trial News

Tags: Cancer, Cirrhosis, Hepatitis C, Influenza, Liver Cancer, Ribavirin, Transplant, Virus

Interim data from Schering-Plough's narlaprevir Phase IIa study

3. November 2009 03:02

Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. [More]

1a7fbbff-144f-40e7-b2ff-2a96b6917170|1|5.0

Posted in: Drug Trial News | Disease/Infection News

Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hepatology, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Liver Cancer, Lupus, Nausea, Neuropathy, Neutropenia, Pancreatitis, Peginterferon alfa, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Ritonavir, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Virus, Vomiting, Weight Loss

Valeant Pharmaceuticals announces financial results for the third quarter of 2009

2. November 2009 08:36

Valeant Pharmaceuticals International today announced third quarter financial results for 2009. [More]

4911f808-8698-4f1f-8d7d-d3b5c6380102|0|.0

Posted in: Business / Finance

Tags: Clindamycin, Dermatology, Neurology, New Drug Application, Ribavirin

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

2. November 2009 06:45

Results from two significant Canadian studies underscore the growing scientific evidence of PEGETRON's positive outcomes in the treatment of chronic hepatitis C virus (HCV) infection. Canadian investigators across the country collaborated to generate and analyze clinical data from the Canadian PEGETRON POWeR (Prospective Optimal Weight-based Dosing Response) and REDIPEN programs, which were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston on November 1, 2009. [More]

2db9a14f-25a4-444b-97c2-369de448e124|0|.0

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Hepatitis C, Peginterferon alfa, Ribavirin, Virus

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

2. November 2009 03:54

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. [More]

8969e6c4-116a-4854-86a2-8b6bb06fa18a|0|.0

Posted in: Drug Trial News

Tags: Cell, Hepatitis C, Interleukin-21, Melanoma, Nausea, Renal Cell Carcinoma, Ribavirin, Virus

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

2. November 2009 03:47

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study. [More]

0f4e6d33-c1f4-4ef6-a92b-7c9b634bfc97|0|.0

Posted in: Medical Procedure News | Medical Condition News

Tags: Biopsy, Fibrosis, Gastroenterology, Hepatitis C, Hospital, Immunosuppression, Ribavirin, Transplant, Virus

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

2. November 2009 03:23

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated. [More]

11534e5d-c858-43a7-ac02-f856bf8d8cd8|0|.0

Posted in: Drug Trial News

Tags: Abdominal Pain, Anemia, Biotechnology, Cancer, CDC, Cirrhosis, Cystic Fibrosis, Fibrosis, Headache, Hepatitis C, Hepatology, Hospital, Jaundice, Nausea, Ribavirin, Telaprevir, Virus

Schering-Plough receives FDA complete response letter regarding PEGINTRON

31. October 2009 03:09

Schering-Plough Corp. announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy. [More]

c3fa1d4f-06bd-4b30-80ad-b27272ea5cd9|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lupus, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Pancreatitis, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Vomiting, Weight Loss

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

30. October 2009 12:32

Researchers in New York City are reporting their work uncovering a new epidemic of hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) who have HIV infection. [More]

43323486-5a16-4564-be81-757ab1548f71|0|.0

Posted in: Men's Health News | Disease/Infection News

Tags: Antibody, Biopsy, CDC, Fibrosis, Hepatitis C, Hepatology, Ribavirin, Virus

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

30. October 2009 08:37

Idenix Pharmaceuticals, Inc.a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in Boston, Massachusetts. [More]

e7a756e4-0df3-4edb-b861-40dac03c832d|1|5.0

Posted in: Drug Trial News | Disease/Infection News

Tags: Diarrhea, Headache, Hepatitis C, Hospital, Ribavirin, Virus

Supportive data from a preclinical study of SCY-635 to be presented

29. October 2009 03:52

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009. [More]

70d2f008-9690-4db8-8276-db2469447bf8|0|.0

Posted in: Pharmaceutical News

Tags: Hepatitis C, Ribavirin, Telaprevir, Virus

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

28. October 2009 01:53

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases. [More]

c054cb7d-4dcc-45c6-b3e4-4aec4470f902|0|.0

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Avian Influenza, Chemotherapy, H1N1, H3N2, H5N1, Hospital, Influenza, Pandemic, Ribavirin, Swine Flu, Virus

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Ribavirin News and Research

Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A

On-going Phase 2b study conducted by Roche of ITMN-191 modified

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Interim data from Schering-Plough's narlaprevir Phase IIa study

Valeant Pharmaceuticals announces financial results for the third quarter of 2009

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Supportive data from a preclinical study of SCY-635 to be presented

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

Recent Articles

Free!

Recent Comments

Twitter

Information

Ribavirin News and Research

Medical News Cloud

Recent Articles